In 2019, IFPMA released a strengthened code of ethics[5] and professional standards.[6] Among the revisions to the code is a prohibition on gifts provided to healthcare professionals.[7] The code revision has been followed by Ethoscope[8] – an open-source, continuously evolving resource that contains diverse guidance designed to keep pace with emerging developments.
The pharmaceutical industry contributes to the Sustainable Development Goals (SDGs), in particular Goal 3 to ensure healthy lives and promote well-being for all at all ages.[9] Today over 35 IFPMA member companies contribute resources and knowhow to SDG initiatives [10] partnering with academia, development organizations, NGOs, foundations and other business sectors. There are over 250 collaborations that aim to strengthen health systems and expand quality healthcare access.[11]
IFPMA works in partnership with other members of the global health community to achieve Universal Health Coverage (UHC) targets and contribute to a world where no one is left behind in receiving the healthcare they need.[12] A wide range of stakeholders across the public and private sectors have an opportunity to collaborate more closely to increase affordability of and access to essential medicines, and the low-cost, but highly effective, interventions and screenings.[13]
Leadership
Since 2022, Dr Albert Bourla, chairman and CEO of Pfizer has served as President and Dr Thomas Schinecker, CEO of Roche serves as Vice-President.
In November 2024, IFPMA announced that Thomas Schinecker would replace Albert Bourla as President. Robert M. Davis, CEO of Merck & Co., and Dr Sunao Manabe, CEO of Daiichi Sankyo, will serve as Vice-Presidents.[14]
